HC Wainwright Predicts Immunocore FY2030 Earnings

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) – Analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Immunocore in a research note issued to investors on Wednesday, February 4th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of $11.26 for the year. HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

Several other brokerages have also recently weighed in on IMCR. UBS Group set a $55.00 price target on Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th. Wells Fargo & Company assumed coverage on shares of Immunocore in a research note on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective for the company. Morgan Stanley increased their target price on shares of Immunocore from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Zacks Research raised shares of Immunocore from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $60.40.

Immunocore Stock Performance

Shares of IMCR opened at $31.50 on Thursday. Immunocore has a 52-week low of $23.15 and a 52-week high of $40.71. The stock’s 50-day simple moving average is $35.10 and its 200 day simple moving average is $34.48. The company has a debt-to-equity ratio of 0.99, a quick ratio of 5.97 and a current ratio of 6.00. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -55.26 and a beta of 0.78.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.32. The firm had revenue of $103.69 million for the quarter, compared to the consensus estimate of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The business’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.17 earnings per share.

Hedge Funds Weigh In On Immunocore

Institutional investors have recently made changes to their positions in the stock. Y Intercept Hong Kong Ltd bought a new position in shares of Immunocore during the 2nd quarter valued at about $1,621,000. Acadian Asset Management LLC lifted its position in Immunocore by 392.3% in the 2nd quarter. Acadian Asset Management LLC now owns 90,798 shares of the company’s stock worth $2,843,000 after buying an additional 72,355 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its stake in Immunocore by 27.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 384,782 shares of the company’s stock worth $12,074,000 after buying an additional 83,612 shares in the last quarter. Eschler Asset Management LLP bought a new position in Immunocore during the second quarter valued at approximately $1,255,000. Finally, State of New Jersey Common Pension Fund D purchased a new position in shares of Immunocore during the second quarter worth approximately $292,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.